HRP20240700T1 - Inhibitor irak4 u kombinaciji sa inhibitorom bcl-2 za uporabu u liječenju raka - Google Patents
Inhibitor irak4 u kombinaciji sa inhibitorom bcl-2 za uporabu u liječenju raka Download PDFInfo
- Publication number
- HRP20240700T1 HRP20240700T1 HRP20240700TT HRP20240700T HRP20240700T1 HR P20240700 T1 HRP20240700 T1 HR P20240700T1 HR P20240700T T HRP20240700T T HR P20240700TT HR P20240700 T HRP20240700 T HR P20240700T HR P20240700 T1 HRP20240700 T1 HR P20240700T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- compound
- use according
- leukemia
- lymphoma
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title claims 10
- 206010028980 Neoplasm Diseases 0.000 title claims 8
- 239000012664 BCL-2-inhibitor Substances 0.000 title claims 5
- 229940123711 Bcl2 inhibitor Drugs 0.000 title claims 5
- 229940127590 IRAK4 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 21
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 6
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 claims 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims 2
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 2
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 claims 2
- 208000017055 digestive system neuroendocrine neoplasm Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 201000004931 neurofibromatosis Diseases 0.000 claims 2
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 208000037244 polycythemia vera Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007275 Carcinoid tumour Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101150053046 MYD88 gene Proteins 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010067387 Myelodysplastic syndrome transformation Diseases 0.000 claims 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 claims 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038272 Refractory anaemia with ringed sideroblasts Diseases 0.000 claims 1
- 208000009527 Refractory anemia Diseases 0.000 claims 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000006938 Schwannomatosis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000013685 acquired idiopathic sideroblastic anemia Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000008274 breast adenocarcinoma Diseases 0.000 claims 1
- 201000000135 breast papillary carcinoma Diseases 0.000 claims 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 208000022013 kidney Wilms tumor Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000005075 mammary gland Anatomy 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 208000030163 medullary breast carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- 201000009494 neurilemmomatosis Diseases 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000023933 refractory anemia with excess blasts in transformation Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002814 testicular lymphoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical group C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 1
- 229960001183 venetoclax Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579502P | 2017-10-31 | 2017-10-31 | |
| PCT/US2018/058194 WO2019089580A1 (en) | 2017-10-31 | 2018-10-30 | Compounds and compositions for treating hematological disorders |
| EP18873778.7A EP3704108B1 (en) | 2017-10-31 | 2018-10-30 | Irak4 inhibitor in combination with a bcl-2 inhibitor for use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240700T1 true HRP20240700T1 (hr) | 2024-08-16 |
Family
ID=66328095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240700TT HRP20240700T1 (hr) | 2017-10-31 | 2018-10-30 | Inhibitor irak4 u kombinaciji sa inhibitorom bcl-2 za uporabu u liječenju raka |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10758518B2 (enExample) |
| EP (2) | EP4410377A3 (enExample) |
| JP (3) | JP7241747B2 (enExample) |
| KR (2) | KR102697663B1 (enExample) |
| CN (2) | CN117064897A (enExample) |
| AU (3) | AU2018359248B2 (enExample) |
| BR (1) | BR112020008214A2 (enExample) |
| CA (1) | CA3079628A1 (enExample) |
| DK (1) | DK3704108T3 (enExample) |
| EA (1) | EA202090497A1 (enExample) |
| ES (1) | ES2979273T3 (enExample) |
| FI (1) | FI3704108T3 (enExample) |
| HR (1) | HRP20240700T1 (enExample) |
| HU (1) | HUE067356T2 (enExample) |
| IL (3) | IL308364B2 (enExample) |
| LT (1) | LT3704108T (enExample) |
| MX (2) | MX2020003666A (enExample) |
| MY (1) | MY203827A (enExample) |
| NZ (1) | NZ762393A (enExample) |
| PH (1) | PH12020550457A1 (enExample) |
| PL (1) | PL3704108T3 (enExample) |
| PT (1) | PT3704108T (enExample) |
| RS (1) | RS65572B1 (enExample) |
| SG (1) | SG11202002386WA (enExample) |
| SI (1) | SI3704108T1 (enExample) |
| SM (1) | SMT202400216T1 (enExample) |
| WO (1) | WO2019089580A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ722019A (en) | 2014-01-13 | 2022-07-01 | Aurigene Discovery Tech Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| IL305150B2 (en) | 2017-03-31 | 2025-03-01 | Aurigene Oncology Ltd | Compounds and preparations for the treatment of hematological disorders |
| SI3704108T1 (sl) * | 2017-10-31 | 2024-07-31 | Curis, Inc. | Inhibitor irak4 v kombinaciji z inhibitorjem bcl-2 za uporabo pri zdravljenju raka |
| JP7353474B2 (ja) * | 2019-09-24 | 2023-09-29 | 上海美悦生物科技発展有限公司 | Ｉｒａｋ阻害剤、その製造方法及び用途 |
| CA3179378A1 (en) | 2020-04-07 | 2021-10-14 | Bayer Aktiengesellschaft | Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances |
| JP2023537477A (ja) * | 2020-08-03 | 2023-09-01 | キュリス，インコーポレイテッド | 疾患及び障害を治療するための組成物及び方法 |
| MX2023005591A (es) * | 2020-11-18 | 2023-05-29 | Curis Inc | Metodos de tratamiento de enfermedades y trastornos. |
| US20230391776A1 (en) * | 2020-12-25 | 2023-12-07 | Medshine Discovery Inc. | Amide oxazole compound |
| EP4319750A4 (en) * | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
| TW202328151A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途 |
| TW202328150A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途 |
| EP4434981A4 (en) * | 2021-12-23 | 2025-08-20 | Hangzhou Polymed Biopharmaceuticals Inc | FIVE- AND SIX-MEMBERED COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION AND ITS USE |
| WO2025090844A1 (en) * | 2023-10-27 | 2025-05-01 | Curis, Inc. | Methods of treating cancer associated with reduced interleukin 1 beta expression |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| ES2102367T3 (es) | 1990-05-18 | 1997-08-01 | Hoechst Ag | Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion. |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| DE69839355T2 (de) | 1997-07-29 | 2009-06-04 | Alcon Laboratories, Inc., Fort Worth | Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat |
| WO1999038504A1 (en) | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| WO2004099156A1 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
| WO2004103954A1 (ja) | 2003-05-20 | 2004-12-02 | Ajinomoto Co., Inc. | アミド誘導体 |
| US20050004133A1 (en) | 2003-06-05 | 2005-01-06 | Makings Lewis R. | Modulators of VR1 receptor |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| US7338950B2 (en) | 2003-10-07 | 2008-03-04 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
| US20090005249A1 (en) | 2004-04-22 | 2009-01-01 | Bayer Cropscience Lp | Method and composition for controlling weeds |
| EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| AU2005304393B2 (en) | 2004-11-10 | 2012-09-27 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| US7838543B2 (en) | 2004-12-17 | 2010-11-23 | Eli Lilly And Company | MCH receptor antagonists |
| ATE446962T1 (de) | 2004-12-17 | 2009-11-15 | Lilly Co Eli | Thiazolopyridinon-derivate als mch- rezeptorantagonisten |
| EP1674467A1 (en) | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| AU2007215247B2 (en) | 2006-02-10 | 2012-12-13 | Transtech Pharma, Llc | Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors |
| GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
| US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| WO2007121154A2 (en) | 2006-04-11 | 2007-10-25 | Janssen Pharmaceutica, N.V. | Substituted benzothiazole kinase inhibitors |
| KR20090049076A (ko) | 2006-09-07 | 2009-05-15 | 바이오겐 아이덱 엠에이 인코포레이티드 | 인터루킨-1 수용체-결합 키나제 조절물질로서 인다졸 유도체 |
| AU2007292924A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| WO2008061109A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| US7998995B2 (en) | 2006-12-08 | 2011-08-16 | Exelixis Patent Company Llc | LXR and FXR modulators |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| EP2170834B1 (en) | 2007-07-16 | 2014-01-08 | AbbVie Inc. | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| JP5508265B2 (ja) | 2007-08-08 | 2014-05-28 | メルク セローノ ソシエテ アノニム | 多発性硬化症の治療のための、スフィンゴシン１−ホスフェート（ｓ１ｐ）受容体に結合する６−アミノ−ピリミジン−４−カルボキサミド誘導体及び関連化合物 |
| US20090221612A1 (en) | 2008-02-13 | 2009-09-03 | Mitchell Scott A | Certain substituted amides, method of making, and method of use thereof |
| WO2010059602A2 (en) | 2008-11-19 | 2010-05-27 | Schering Corporation | Inhibitors of diacylglycerol acyltransferase |
| US8283360B2 (en) | 2008-12-19 | 2012-10-09 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic derivatives and methods of use thereof |
| SG172382A1 (en) | 2008-12-23 | 2011-07-28 | Hoffmann La Roche | Dihydropyridone ureas as p2x7 modulators |
| PL2488486T3 (pl) | 2009-10-13 | 2020-01-31 | Ligand Pharmaceuticals Inc. | Małocząsteczkowe związki mimetyczne hematopoetycznego czynnika wzrostu i ich zastosowania |
| CN102939283B (zh) | 2010-04-22 | 2015-06-03 | 詹森药业有限公司 | 可用作己酮糖激酶抑制剂的吲唑化合物 |
| CA2793697A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Inhibitors of phosphoinositide dependent kinase 1 (pdk1) |
| SI2585064T1 (sl) | 2010-06-24 | 2017-08-31 | Chemocentryx, Inc. | Antagonisti C5AR |
| MX340490B (es) | 2010-07-13 | 2016-07-11 | F Hoffmann-La Roche Ag * | Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4). |
| CN103298792A (zh) | 2010-11-19 | 2013-09-11 | 利亘制药公司 | 杂环胺及其用途 |
| JP6007189B2 (ja) | 2010-12-20 | 2016-10-12 | メルク セローノ ソシエテ アノニム | Ｉｒａｋ阻害剤としてのインダゾリルトリアゾール誘導体 |
| CN103608017B (zh) | 2011-04-12 | 2017-02-15 | 美国卫生和人力服务部 | 用于治疗或预防疟疾的疟原虫表面阴离子通道抑制剂 |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| US9957271B2 (en) | 2011-10-20 | 2018-05-01 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| KR101385603B1 (ko) | 2012-05-17 | 2014-04-21 | 한국원자력의학원 | 벤조티아졸 유도체 및 암 치료를 위한 그의 용도 |
| WO2014003483A1 (en) | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
| EP2872144A4 (en) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
| EP2914592B1 (en) | 2012-11-03 | 2017-10-11 | Boehringer Ingelheim International GmbH | Inhibitors of cytomegalovirus |
| CA2907960C (en) | 2013-05-22 | 2021-10-19 | Children's Hospital Medical Center | Combination therapy for mds |
| TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| WO2015104662A1 (en) * | 2014-01-10 | 2015-07-16 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| NZ722019A (en) * | 2014-01-13 | 2022-07-01 | Aurigene Discovery Tech Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| BR112016017996A2 (pt) | 2014-02-06 | 2017-08-08 | Abbvie Inc | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso |
| MX2016017147A (es) | 2014-06-20 | 2017-06-07 | Aurigene Discovery Tech Ltd | Compuestos de indazole substituidos como inhibidores de irak4. |
| US20180201609A1 (en) | 2015-07-15 | 2018-07-19 | Aurigene Discovery Technologies Limited | Indazole and azaindazole compounds as irak-4 inhibitors |
| AU2016293446A1 (en) | 2015-07-15 | 2018-02-15 | Aurigene Discovery Technologies Limited | Substituted aza compounds as IRAK-4 inhibitors |
| CA2993661A1 (en) * | 2015-08-04 | 2017-02-09 | Rigel Pharmaceuticals, Inc. | Benzazole compounds and methods for making and using the compounds |
| CA3038130A1 (en) | 2016-10-28 | 2018-05-03 | Children's Hospital Medical Center | Treatment of diseases associated with activated irak |
| SI3704108T1 (sl) * | 2017-10-31 | 2024-07-31 | Curis, Inc. | Inhibitor irak4 v kombinaciji z inhibitorjem bcl-2 za uporabo pri zdravljenju raka |
-
2018
- 2018-10-30 SI SI201831106T patent/SI3704108T1/sl unknown
- 2018-10-30 SG SG11202002386WA patent/SG11202002386WA/en unknown
- 2018-10-30 DK DK18873778.7T patent/DK3704108T3/da active
- 2018-10-30 PT PT188737787T patent/PT3704108T/pt unknown
- 2018-10-30 PL PL18873778.7T patent/PL3704108T3/pl unknown
- 2018-10-30 BR BR112020008214-7A patent/BR112020008214A2/pt unknown
- 2018-10-30 KR KR1020207013352A patent/KR102697663B1/ko active Active
- 2018-10-30 AU AU2018359248A patent/AU2018359248B2/en active Active
- 2018-10-30 FI FIEP18873778.7T patent/FI3704108T3/fi active
- 2018-10-30 IL IL308364A patent/IL308364B2/en unknown
- 2018-10-30 HU HUE18873778A patent/HUE067356T2/hu unknown
- 2018-10-30 MY MYPI2020001530A patent/MY203827A/en unknown
- 2018-10-30 ES ES18873778T patent/ES2979273T3/es active Active
- 2018-10-30 EA EA202090497A patent/EA202090497A1/ru unknown
- 2018-10-30 CN CN202311020285.0A patent/CN117064897A/zh active Pending
- 2018-10-30 IL IL274248A patent/IL274248B2/en unknown
- 2018-10-30 SM SM20240216T patent/SMT202400216T1/it unknown
- 2018-10-30 KR KR1020247027492A patent/KR20240130818A/ko active Pending
- 2018-10-30 NZ NZ762393A patent/NZ762393A/en unknown
- 2018-10-30 EP EP24168755.7A patent/EP4410377A3/en active Pending
- 2018-10-30 CN CN201880066904.0A patent/CN111225911B/zh active Active
- 2018-10-30 RS RS20240586A patent/RS65572B1/sr unknown
- 2018-10-30 HR HRP20240700TT patent/HRP20240700T1/hr unknown
- 2018-10-30 IL IL315025A patent/IL315025A/en unknown
- 2018-10-30 CA CA3079628A patent/CA3079628A1/en active Pending
- 2018-10-30 EP EP18873778.7A patent/EP3704108B1/en active Active
- 2018-10-30 LT LTEPPCT/US2018/058194T patent/LT3704108T/lt unknown
- 2018-10-30 JP JP2020523028A patent/JP7241747B2/ja active Active
- 2018-10-30 WO PCT/US2018/058194 patent/WO2019089580A1/en not_active Ceased
- 2018-10-30 MX MX2020003666A patent/MX2020003666A/es unknown
- 2018-10-31 US US16/176,940 patent/US10758518B2/en active Active
-
2020
- 2020-04-21 PH PH12020550457A patent/PH12020550457A1/en unknown
- 2020-07-13 MX MX2023010882A patent/MX2023010882A/es unknown
- 2020-07-21 US US16/934,724 patent/US20200345704A1/en not_active Abandoned
-
2021
- 2021-12-30 US US17/566,371 patent/US20220370422A1/en not_active Abandoned
-
2023
- 2023-03-07 JP JP2023034551A patent/JP7476380B2/ja active Active
- 2023-08-30 AU AU2023222890A patent/AU2023222890B2/en active Active
-
2024
- 2024-04-17 JP JP2024066487A patent/JP2024096919A/ja not_active Withdrawn
-
2025
- 2025-07-10 AU AU2025205341A patent/AU2025205341A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240700T1 (hr) | Inhibitor irak4 u kombinaciji sa inhibitorom bcl-2 za uporabu u liječenju raka | |
| JP2021501145A5 (enExample) | ||
| PH12020551507A1 (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
| MX2021003517A (es) | Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso. | |
| MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
| IL299099B1 (en) | Combinations of cancer treatments | |
| MX2021008610A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| ME00937B (me) | Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera | |
| MX2017015226A (es) | Compuestos alqueno tetrasustituidos y su uso. | |
| JP2018528206A5 (enExample) | ||
| CN104436194B (zh) | 具有协同增效作用的抗癌组合物 | |
| MY197558A (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| JP2016528162A5 (enExample) | ||
| MX2020009842A (es) | Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido. | |
| RU2018138627A (ru) | Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| EA201791946A1 (ru) | Лечение хронической реакции "трансплантат против хозяина" с применением ингибиторов syk | |
| RU2018102087A (ru) | Производное 1,4-дизамещенного имидазола | |
| TN2012000110A1 (en) | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| JP2016522202A5 (enExample) | ||
| TW201613577A (en) | Pharmaceutical combinations |